Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Vicriviroc represents a promising new candidate for the treatment of HIV-1 infection
InChi: InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16
PubMed PMID: 15698853
InChiKey: SDGDWRYYHQOQOJ-QBGQQMMYSA-N
Loxapine succinate - CAS# 27833-64-3 oxy)-1 6-dihydroxy-2-methyl-9 10-anthracenedione Vicriviroc represents a promising newLoxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti psychotic agent. IC50 value: Target: D2DR D4DR; 5 HT receptor in vitro: In the presence of Loxapine, [3H]ketanserin binds to 5 HT2 receptor in Frontal cortex of brain in human and bovine with ki value of 6. 2 nM and 6. 6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows: 5
US$ 166.00
US$ 113.00
US$ 21.80
US$ 23.70
US$ 172.00
US$ 469.00